| 132747-47-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• CAS: 132747-47-8
• 化学式: C20H27CaNO4S
• 分子量: 417.6
• InChiKey: NYPRFAXLCNIUHC-GWSYSLRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• QUATERNARY AMMONIUM SALT COMPOUNDS
  申请人：Mitsuyama Etsuko

  公开号：US20120046467A1

  公开（公告）日：2012-02-23

  [Problem] The object of the present invention is to provide a novel compound having 132 adrenergic receptor agonist activity and muscarinic receptor antagonist activity. [Means for Solving the Problem] The present invention is a quaternary ammonium salt compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, with superior β32 adrenergic receptor agonist activity and muscarinic receptor antagonist activity.

  本发明的目的是提供一种具有132肾上腺素受体激动剂活性和肌制剂受体拮抗活性的新型化合物。本发明是一种由化学式(I)表示的季铵盐化合物，或其在药学上可接受的盐，具有优越的β32肾上腺素受体激动剂活性和肌制受体拮抗活性。
• AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1849465A1

  公开（公告）日：2007-10-31

  The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5-to 7-membered ring, V is a bond or the group represented by the formula -CR14=CR15 - or - N=CR16- (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof

  本发明提供了一种 GPR 受体功能调节剂，包括由式表示的化合物： [其中环A是任选取代的异环或杂环，P是键或间隔物，环D是任选取代的单环芳香环，可与5-7元环缩合，V是键或由式-CR14＝CR15-或-N＝CR16-代表的基团（其中R14、R15 和 R16 各代表一个氢原子或任选取代的烃基），Q 是键或间隔物，W 是羧基或生物等价于羧基的基团]或其盐或其原药
• QUATERNARY AMMONIUM SALT COMPOUND
  申请人：Teijin Pharma Limited

  公开号：EP2426121A1

  公开（公告）日：2012-03-07

  [Problem] The abject of the present invention is to provide a novel compound having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity. [Means for Salving the Problem The present invention is a quaternary ammonium salt compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, with superior β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity.

  问题 本发明的目的是提供一种具有β2肾上腺素能受体激动剂活性和毒蕈碱受体拮抗剂活性的新型化合物。 [解决问题的方法 本发明是一种由式（I）代表的季铵盐化合物或其药学上可接受的盐，具有优异的 β2肾上腺素能受体激动剂活性和毒蕈碱受体拮抗剂活性。
• HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY
  申请人：Shanghai Dude Medical Technology Co., Ltd

  公开号：EP3643716A1

  公开（公告）日：2020-04-29

  The present invention provides a class of novel compounds having Btk selective inhibitory activity, better metabolic stability and the like.

  本发明提供了一类具有 Btk 选择性抑制活性、更好的代谢稳定性等特点的新型化合物。
• PURINONE DERIVATIVE AS BTK KINASE INHIBITOR
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP3112368B1

  公开（公告）日：2020-02-12